The addition of idarucizumab to plasma samples containing dabigatran allows the use of routine coagulation assays for the diagnosis of hemostasis disorders

被引:34
作者
Jacquemin, M. [1 ,2 ]
Toelen, J. [2 ]
Schoeters, J. [2 ]
van Horenbeeck, I. [2 ]
Vanlinthout, I. [2 ]
Debasse, M. [2 ]
Peetermans, M. [2 ]
Vanassche, T. [1 ,3 ]
Peerlinck, K. [1 ,3 ]
van Ryn, J. [4 ]
Verhamme, P. [1 ,3 ]
机构
[1] Univ Leuven, Ctr Mol & Vasc Biol, Dept Cardiovasc Sci, B-3000 Leuven, Belgium
[2] Univ Hosp Leuven, Dept Clin Lab Med, Leuven, Belgium
[3] Univ Hosp Leuven, Vasc Med & Hemostasis, Leuven, Belgium
[4] Boehringer Ingelheim Pharma GmbH & Co KG, Dept CardioMetab Dis Res, Biberach, Germany
关键词
dabigatran; hemophilia A; idarucizumab; lupus anticoagulant; thrombophilia; THROMBIN TIME; DOUBLE-BLIND; LC-MS/MS; WARFARIN; PLACEBO; TESTS;
D O I
10.1111/jth.13138
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The anticoagulant effect of dabigatran can be approximated by its prolongation of routine coagulation assays. Consequently, dabigatran also interferes with thrombophilia screening or with diagnosing hemostasis disorders that have developed after the initiation of anticoagulant treatment, such as vitamin K deficiency or acquired hemophilia A. Objectives: This study was carried out to determine whether idarucizumab, a humanized antibody fragment that binds dabigatran, could fully neutralize dabigatran in routine diagnostic coagulation assays conducted in vitro, thereby preventing false-positive or false-negative diagnostic readouts. Methods: Preliminary experiments identified coagulation assays that were sensitive to dabigatran, and identified a concentration of idarucizumab that neutralized the effects of dabigatran. These assays were then carried out with patient and control plasma samples spiked with dabigatran, with or without a molar excess of idarucizumab. Results: Dabigatran altered the prothrombin time, activated partial thromboplastin time and thrombin time, and the measurement of intrinsic and extrinsic factor levels. Screening and confirmation tests used for lupus anticoagulant detection were prolonged by dabigatran, falsely suggesting the presence of lupus anticoagulant. Conversely, the addition of dabigatran falsely corrected an abnormal activated protein C resistance ratio. Addition of idarucizumab completely normalized these measurements, and allowed the correct identification of normal and abnormal samples with these assays. Conclusions: In vitro addition of idarucizumab to plasma samples containing dabigatran fully neutralizes the drug, and facilitates the use of routine coagulation assays to allow the diagnosis of hemostasis disorders that may be concurrently present in patients taking dabigatran.
引用
收藏
页码:2087 / 2092
页数:6
相关论文
共 23 条
  • [1] The Effect of Dabigatran on Select Specialty Coagulation Assays
    Adcock, Dorothy M.
    Gosselin, Robert
    Kitchen, Steve
    Dwyre, Denis M.
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2013, 139 (01) : 102 - 109
  • [2] Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma
    Antovic, Jovan P.
    Skeppholm, Mika
    Eintrei, Jaak
    Boija, Elisabet Eriksson
    Soderblom, Lisbeth
    Norberg, Eva-Marie
    Onelov, Liselotte
    Ronquist-Nii, Yuko
    Pohanka, Anton
    Beck, Olof
    Hjemdahl, Paul
    Malmstrom, Rickard E.
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 69 (11) : 1875 - 1881
  • [3] Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: Guidance from the British Committee for Standards in Haematology
    Baglin, Trevor
    Keeling, David
    Kitchen, Steve
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2012, 159 (04) : 427 - 429
  • [4] Dabigatran versus Warfarin in Patients with Atrial Fibrillation.
    Connolly, Stuart J.
    Ezekowitz, Michael D.
    Yusuf, Salim
    Eikelboom, John
    Oldgren, Jonas
    Parekh, Amit
    Pogue, Janice
    Reilly, Paul A.
    Themeles, Ellison
    Varrone, Jeanne
    Wang, Susan
    Alings, Marco
    Xavier, Denis
    Zhu, Jun
    Diaz, Rafael
    Lewis, Basil S.
    Darius, Harald
    Diener, Hans-Christoph
    Joyner, Campbell D.
    Wallentin, Lars
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (12) : 1139 - 1151
  • [5] Dabigatran Effects on the International Normalized Ratio, Activated Partial Thromboplastin Time, Thrombin Time, and Fibrinogen: A Multicenter, In Vitro Study
    Dager, William E.
    Gosselin, Robert C.
    Kitchen, Steve
    Dwyre, Dennis
    [J]. ANNALS OF PHARMACOTHERAPY, 2012, 46 (12) : 1627 - 1636
  • [6] Estimation of dabigatran plasma concentrations in the perioperative setting An ex vivo study using dedicated coagulation assays
    Douxfils, Jonathan
    Lessire, Sarah
    Dincq, Anne-Sophie
    Hjemdahl, Paul
    Ronquist-Nii, Yuko
    Pohanka, Anton
    Gourdin, Maximilien
    Chatelain, Bernard
    Dogne, Jean-Michel
    Mullier, Francois
    [J]. THROMBOSIS AND HAEMOSTASIS, 2015, 113 (04) : 862 - 869
  • [7] Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate
    Douxfils, Jonathan
    Dogne, Jean-Michel
    Mullier, Francois
    Chatelain, Bernard
    Ronquist-Nii, Yuko
    Malmstrom, Rickard E.
    Hjemdahl, Paul
    [J]. THROMBOSIS AND HAEMOSTASIS, 2013, 110 (03) : 543 - 549
  • [8] Impact of dabigatran on a large panel of routine or specific coagulation assays Laboratory recommendations for monitoring of dabigatran etexilate
    Douxfils, Jonathan
    Mullier, Francois
    Robert, Severine
    Chatelain, Christian
    Chatelain, Bernard
    Dogne, Jean-Michel
    [J]. THROMBOSIS AND HAEMOSTASIS, 2012, 107 (05) : 985 - 997
  • [9] Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement:: a randomised, double-blind, non-inferiority trial
    Eriksson, Bengt I.
    Dahl, Ola E.
    Rosencher, Nadia
    Kurth, Andreas A.
    van Dijk, C. Niek
    Frostick, Simon P.
    Prins, Martin H.
    Hettiarachchi, Rohan
    Hantel, Stefan
    Schnee, Janet
    Bueller, Harry R.
    [J]. LANCET, 2007, 370 (9591) : 949 - 956
  • [10] Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial
    Glund, Stephan
    Stangier, Joachim
    Schmohl, Michael
    Gansser, Dietmar
    Norris, Stephen
    van Ryn, Joanne
    Lang, Benjamin
    Ramael, Steven
    Moschetti, Viktoria
    Gruenenfelder, Fredrik
    Reilly, Paul
    Kreuzer, Joerg
    [J]. LANCET, 2015, 386 (9994) : 680 - 690